Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients1
The most common AEs reported in 5%-25% of patients across 5 clinical studies1*
Instillation-site
irritation
Dysgeusia
Reduced
visual acuity
*In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least 1 dose of lifitegrast (1287 of whom received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure; 170 patients were exposed to Xiidra for approximately 12 months.1
The majority of treatment-emergent AEs were mild to moderate in severity
Values inside bars=number of participants.
†The 1-year, multicenter, randomized, prospective, double-masked, placebo-controlled, phase 3 SONATA study evaluated the safety of Xiidra compared to vehicle in 331 adult patients who had a self-reported history of dry eye disease. Artificial tear use was assessed as an exploratory endpoint.2
‡Adverse events occurring in >5% of participants in either treatment group.2
§In the SONATA study, a total of 24 participants (Xiidra, 8.2% [18/220] vs vehicle, 5.4% [6/111]) had at least 1 ocular treatment-emergent adverse event (TEAE) and 13 participants had at least 1 nonocular TEAE (Xiidra, 4.1% [9/220] vs vehicle, 3.6% [4/111]) that resulted in discontinuation.2
∥Percentage value indicates the proportion of participants who experienced each type of adverse event.2
Among participants treated with Xiidra in the SONATA safety study and a pooled analysis of four 12-week studies3
discontinued due to instillation-site reaction and dysgeusia3
discontinued due to instillation-site irritation or pain3
discontinued due to reduced visual acuity2
Patients taking Xiidra had the lowest discontinuation rate after their first Rx compared with cyclosporine4¶
Nearly 88% of patients remained on Xiidra after 1 year in the SONATA safety study2†
In addition to potential AEs,
every patient prescribed Xiidra should know
Drop comfort score improvements were seen across 3 clinical trials from 2 weeks to 12 weeks at 3 minutes post instillation3-6¶
Dr Preeya Gupta, Ophthalmologist, Triangle Eye Consultants
~90% overall coverage for commercial and Medicare Part D patients nationwide7#
AE, adverse event.
†The 1-year, multicenter, randomized, prospective, double-masked, placebo-controlled, phase 3 SONATA study evaluated the safety of Xiidra compared to vehicle in 331 adult patients who had a self-reported history of dry eye disease. Artificial tear use was assessed as an exploratory endpoint.2
¶Drop comfort was measured based on patient-reported scores from 0 (very comfortable) to 10 (very uncomfortable).3
#Based on data from April 2024. Up to 95% of commercial and 71% of Medicare Part D patients may be covered.7
**Xiidra significantly reduced symptoms of eye dryness at 2 weeks (based on Eye Dryness Score compared to vehicle) in 2 of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1
References
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).